文献速递神经肿瘤

立体定向放射外科治疗视神经旁脑膜瘤:国际多中心研究

Stereotactic Radiosurgery for Perioptic Meningiomas: An International, Multicenter Study.
PubMed 文献 · Neurosurgery · 2021-01-01

该研究基于国际放射外科研究基金会12家机构438例视神经旁脑膜瘤患者,回顾性评估立体定向放射外科的安全性与有效性。中位随访55.6个月,5年与10年无进展生存率分别为96%和89%,10%患者出现视力下降。处方剂量≥12 Gy与单次照射与更好肿瘤控制相关,视路最大剂量≥10 Gy和肿瘤进展是视力下降的独立预测因素。

要点

  • 处方剂量≥12 Gy和单次照射与更好的肿瘤控制相关
  • 视路最大剂量≥10 Gy和肿瘤进展是放疗后视力下降的独立预测因素
  • 视神经旁脑膜瘤SRS可获得持久肿瘤控制和可接受的视力保全率

核心结论

  • SRS为视神经旁脑膜瘤提供持久的肿瘤控制和相当可接受的视力保全率。
  • 边缘剂量≥12 Gy与更好的肿瘤控制相关。
  • 视路剂量≥10 Gy和肿瘤进展与SRS后视力下降相关。

研究设计与样本

  • 国际放射外科研究基金会(IRRF)12家机构参与的多中心回顾性研究。
  • 纳入438例组织学确诊(29%)或影像学怀疑(71%)的视神经旁脑膜瘤患者,肿瘤位于视路3 mm以内。
  • 中位年龄51岁,中位治疗体积8.01 cm3。
  • 405例(93%)接受单次SRS,33例(7%)接受大分割SRS。

主要发现

  • 中位影像随访55.6个月(范围3.15-239个月),33例(8%)出现肿瘤进展。
  • 5年和10年无进展生存率分别为96%和89%。
  • 31例(10%)出现视力下降,5年和10年SRS后视力下降率分别为9%和21%。

关键数值与推荐

  • 中位处方剂量12 Gy,中位视路剂量8.50 Gy。

临床怎么用

  • 对位于视路3 mm以内的脑膜瘤,SRS可作为治疗选择之一。
  • 规划时关注处方剂量≥12 Gy以改善肿瘤控制,同时控制视路最大剂量以降低视力下降风险。
  • 单次SRS在肿瘤控制方面显示优势,但需结合个体情况权衡。
  • SRS后需监测肿瘤进展,因其与视力下降独立相关。

局限性

  • 回顾性多中心研究设计。
  • 部分肿瘤为影像学怀疑而非组织学确诊(71%)。
  • 随访时间范围差异较大(3.15-239个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic radiosurgery (SRS) is increasingly used for management of perioptic meningiomas. OBJECTIVE: To study the safety and effectiveness of SRS for perioptic meningiomas. METHODS: From 12 institutions participating in the International Radiosurgery Research Foundation (IRRF), we retrospectively assessed treatment parameters and outcomes following SRS for meningiomas located within 3 mm of the optic apparatus. RESULTS: A total of 438 patients (median age 51 yr) underwent SRS for histologically confirmed (29%) or radiologically suspected (71%) perioptic meningiomas. Median treatment volume was 8.01 cm3. Median prescription dose was 12 Gy, and median dose to the optic apparatus was 8.50 Gy. A total of 405 patients (93%) underwent single-fraction SRS and 33 patients (7%) underwent hypofractionated SRS. During median imaging follow-up of 55.6 mo (range: 3.15-239 mo), 33 (8%) patients experienced tumor progression. Actuarial 5-yr and 10-yr progression-free survival was 96% and 89%, respectively. Prescription dose of ≥12 Gy (HR: 0.310; 95% CI [0.141-0.679], P = .003) and single-fraction SRS (HR: 0.078; 95% CI [0.016-0.395], P = .002) were associated with improved tumor control. A total of 31 (10%) patients experienced visual decline, with actuarial 5-yr and 10-yr post-SRS visual decline rates of 9% and 21%, respectively. Maximum dose to the optic apparatus ≥10 Gy (HR = 2.370; 95% CI [1.086-5.172], P = .03) and tumor progression (HR = 4.340; 95% CI [2.070-9.097], P < .001) were independent predictors of post-SRS visual decline. CONCLUSION: SRS provides durable tumor control and quite acceptable rates of vision preservation in perioptic meningiomas. Margin dose of ≥12 Gy is associated with improved tumor control, while a dose to the optic apparatus of ≥10 Gy and tumor progression are associated with post-SRS visual decline.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Bunevicius A, Anand RK, Suleiman M, et al. Stereotactic Radiosurgery for Perioptic Meningiomas: An International, Multicenter Study. Neurosurgery. 2021. PMID: 33475718. doi:10.1093/neuros/nyaa544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。